Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Resmed Inc (NY: RMD )

147.87 -2.18 (-1.45%)
Official Closing Price Updated: 7:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Resmed Inc

< Previous 1 2 3 4 5 6 7 Next >
Looking Into ResMed's Recent Short Interest
Via Benzinga
Here's How Much $100 Invested In ResMed 20 Years Ago Would Be Worth Today
Via Benzinga
Peering Into ResMed's Recent Short Interest
Via Benzinga
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
From ResMed Inc.
Via GlobeNewswire
ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software
From ResMed Inc.
Via GlobeNewswire
$1000 Invested In This Stock 15 Years Ago Would Be Worth $11,000 Today
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Via Benzinga
Here's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years
Via Benzinga
PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP
From ResMed Inc.
Via GlobeNewswire
ResMed Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023
From ResMed Inc.
Via GlobeNewswire
A Bullish Sign Appears On ResMed's Chart
Via Benzinga
ResMed Earnings Perspective: Return On Capital Employed
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,300 Today
Via Benzinga
Expert Ratings for ResMed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Via Benzinga
Electronic Arts, TD SYNNEX And 2 Other Stocks Insiders Are Selling
The Nasdaq index closed lower on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer
From ResMed Inc.
Via GlobeNewswire
$1000 Invested In ResMed 5 Years Ago Would Be Worth This Much Today
Via Benzinga
$100 Invested In ResMed 5 Years Ago Would Be Worth This Much Today
Via Benzinga
What's Going On With ResMed Stock Today
ResMed Inc (NYSE: RMD) posted Q3 profits of $247.8 million, with adjusted EPS of $1.68, up from $1.32 a year ago, beating the consensus of $1.59. Revenues increased 29% to $1.12 billion, as continued... 
Via Benzinga
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2023
Year-over-year revenue grows 29%, operating profit up 28%, non-GAAP operating profit up 27% 
From ResMed Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
Via Benzinga
Earnings Scheduled For April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
ResMed to Report Third Quarter Fiscal 2023 Earnings on April 27, 2023
From ResMed Inc.
Via GlobeNewswire
ResMed Chief Administrative Officer and Global General Counsel to Retire
From ResMed Inc.
Via GlobeNewswire
3 Incredible Growth Stocks to Buy Right Now
These mid-cap growth stocks could deliver market-beating returns in 2023 and beyond. 
Via The Motley Fool
ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum
From ResMed Inc.
Via GlobeNewswire
ResMed’s Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep
From ResMed Inc.
Via GlobeNewswire
ResMed Announces Participation in the Oppenheimer 33rd Annual Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.